Horizon Discovery CEO Darrin Disley wins Executive of the Year award at the SCRIP Awards 2014
The Executive of the Year Award acknowledges excellence in the leadership of large and small pharmaceutical and biotechnology companies. Dr. Disley has spearheaded the transformation of Horizon from start-up to one of the world’s leaders in the creation of tools for personalized medicine. From the Company’s launch in 2007 through 2013 he raised over £20 million in funding and defined the business model of building a company committed to accelerating the discovery of targeted personalized medicines, enabling the delivery of the right drugs to the right patient. Under his leadership, Horizon has gone from strength to strength, generating revenue growth on a compound basis of 126% in the six years to 2013. Further, he oversaw the listing of Horizon on the London Stock Exchange’s AIM market, generating £69 million in funding, nearly three times the original fund-raising goal, supporting the Company through its next phase of growth. Since the IPO he has overseen two M&A transactions including the combination screening services business CombinatoRx based in Cambridge, Massachusetts and the world-leading in vivo gene-editing business SAGE Labs based in St Louis, Missouri and Boyertown, Pennsylvania.
Since the float, Darrin has continued to drive the business with targeted acquisitions into fast-growing areas of the personalized medicines space and by expanding the suite of products and services available to customers, bolstering Horizon’s intellectual property through licensing agreements, and delivering high-value contracts with world-leading life sciences companies.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.